PIK3CA and neoplasm: On the basis of studies from our lab and others demonstrating that PI3K inhibition enhances eribulin efficacy in TNBC (18, 38), we tested whether the pan-PI3K inhibitor copanlisib could improve tumor response to eribulin in a panel of TNBC PDX models.